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INTRODUCTION
One of the main goals in histocompatibility re-
search ought to be the identification of non-HLA
loci important in graft-versus-host disease (GvHD)
and graft rejection. Even if this were achieved, it
would only help the clinician identify those patients
with HLA-identical siblings who have a minimal
risk of GvHD or graft rejection. Although an im-
portant contribution, it would not solve the prob-
lem of what to do for those patients who do not
have an HLA-identical sibling donor who is also
identical at these non-HLA loci. In fact, with in-
creasing selectivity based on better typing, the
number of these problem patients increases. For
such patients who have no related donor, help
could come from two directions:
1. The use of unrelated donors compatible for
HL Α and non-HLA loci. However, we need to
know whether matching for HLA between un-
related donor-recipient pairs can reach the same
degree of compatibility as that between siblings.
2. More effective immunosuppression.
WHAT PROGRESS HAS BEEN MADE
IN RECOGNIZING NON-HLA
ANTIGENS?
Successful platelet transfusion holds a key position
in bone marrow transplantation, especially in sus-
taining the patient during and after bone marrow
transplantation. In hyperimmunized patients, only
about 60 percent of the platelet transfusions will be
successful if HLA-matched platelets are used (3).
The Seattle bone marrow transplant group has
shown that GvHD is more serious in patients who
are resistant to platelet transfusions (26). The pos-
sibility of matching for platelet antigens and pre-
venting immunization to them are thus important
goals in bone marrow transplantation and will be
discussed first. Following the lead of the Seattle
group, several studies have shown that the prog-
nosis of bone marrow transplantation, especially as
determined by GvHD, is poorer when the donor is
a female and the recipient a male (Table 20-1)
(1,11,26). The question one is confronted with is
whether this is due to an in vitro detectable im-
munity against the H-Y antigen, as has been de-
scribed in rodents. This question is especially rel-
evant because not all sex-mismatched grafts fail
because of GvHD, and such an in vitro test would
make it possible to identify which donor-recipient
pairs were at risk for GvHD.
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TABLE 20-1 Successful Bone Marrow Transplantation in Males
FRACTION OF SURVIVORS
DONOR/RECIPIENT
Seattle Ε Β Μ Τ S C I D c International Bone Marrow
series" senesb Transplant Registry Report"1
M-» Μ
ρ Value
8/9
7/18
0.02
17/24
5/21
0.002
15/32
5/25
0.03
aStorb et al. (26).
"European Bone Marrow Transplant (EBMT) Cooperative Group (11)
cSevere combined immunodeficiency disease.
"JAMA (1).
PLATELET ANTIGENS
Brand et al. have recently shown that a near 100
percent success rate can be achieved if HLA
matching is supplemented by a sensitive platelet
cross-match by an immunofluorescence technique
(3). With this technique, a set of non-HLA antigens
can be recognized.
It can be anticipated, however, that the inci-
dence of hyperimmunized patients will diminish.
Eernisse has shown that sensitization by platelet
transfusion can be prevented in over 70 percent of
the patients by the use of platelets that have been
centrifuged three times and that contain virtually
no lymphocytes (8). Eernisse's contribution is thus
of direct importance in clinical bone marrow trans-
plantation because of the already-mentioned fact
that GvHD is more severe in platelet-resistant pa-
tients (26).
H-Y IMMUNITY
Goulmy et al. studied six hyperimmunized women
for evidence of anti-H-Y immunity using the cell-
mediated lympholyses (CML) test (16). They found
significant evidence for such immunity in two pa-
tients, both of whom were suffering from aplastic
anemia and one of whom had received a bone mar-
row transplant. It is of interest that this immunity
is only evident when both the female effector cells
and the male target cells carry HLA-A2 (Table 20-
2). It remains to be determined whether this test
really predicts H-Y dependent GvHD. Neverthe-
less, its relevance in allograft reactions is empha-
sized by the finding that male donor-female recip-
ient kidney grafts that share HLA-A2 have a 2-year
graft survival of 38 percent, whereas if they both
lack HLA-A2, it is 58 percent (15).
The HLA-A2 restricted H-Y immunity is the
first example in man of the dual recognition phe-
nomen that has for some time been recognized in
the mouse (33). In mouse Systems, the restriction
TABLE 20-2 Sex-related Kill mg in CML of HLA-/
itive Target Cells
SEX OF HL·
POSITIVE TA
KILL
(PERCENT) Μ
CML
by Mrs. R.'s
effector cellsa
CML
by Mrs. K.'s
effector cellsa
>30
10-20
< 10
>30
10-20
< 10
15
0
0
6
0
0
aThe effector cells were HLA-A2 positive.
phenomenon has been described not only fr
but also for microbial and artificial antigens
The precise mechanism of the dual recognitic
nomenon is not known.
The HLA-A2 restricted H-Y immunity
demonstrated for more than a year after ir
zation, but it eventually wanes. It can, ho
be reactivated in vitro by Stimulation with un
HLA-A, HLA-B, and HLA-C identical, bul
D different lymphocytes.
The serum from one of these patients (M
was also examined for serological activity
H-Y. The Standard, two-step complement-d
ent cytotoxicity (CdC) technique was negati
van Leeuwen was able to show that a tw
fluorescence technique, which enabled the
nition of CdC directed to identifiable sub
mononuclear cells showed antibodies that ι
with HLA-A2 male donors (Table 20-3) (23
TABLE 20-3 HLA-A2 Restricted Anti-H-Y Immi
Detected by Serology
TWO-COLOR
FLUORESCENCE
CYTOTOXICITY
TEST
CELL-MEDIATE
LYMPHOLYSIS
Positive Neg
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a. fraction of the mononuclear cells that were not
typical B-cells were killed.
The Interpretation of these two sets of data is
difflcult. In the case of the CML reactiön, one can
conceive of two hypotheses. In the first, the killer
cell carries two receptors, one for HLA-A2 and one
for H-Y. In the second, the killer cell carries one
receptor directed to a neoantigen generated in an
interaction between HLA-A2 and H-Y.
The serological reactions must be considered
separately. Here, there are three possibilities. First,
we would be dealing with two antibodies produced
by two clones of B-cells directed to HLA-A2 and
H-Y; second, we could be dealing with an antibody
directed to an neoantigen produced by HLA-A2
and H-Y; and third, it could be that all three anti-
bodies, HLA-A2, H-Y, and the antibody raised by
the neoantigen, reacting together are needed for
killing to occur. It should be possible to determine
which of these situations exists.
It can be said that progress is being made in two
areas that are relevant to bone marrow transplant
survival. These are platelet alloantigens and im-
munity to sex-linked transplantation antigens.
There are, of course, many more non-HLA Sys-
tems. The compatibility of some of these Systems,
such as the ABO blood group System and the tissue
System group Five, have been shown not to be rel-
evant to bone marrow transplantation (4,21). For
others, such as the granulocyte Systems (NA, NB,
14) and the endothelial and monocyte System E,
relevancy has not been tested for (18,19,24). For
none of these Systems, with the exception of the
ABO System, has it been ascertained by cross-
matching procedures whether circulating anti-
bodies against these Systems in the recipient could
cause the rejection of the bone marrow graft. It
appears to us to be a point of some urgency to find
out whether this is so. The Seattle group and Jean-
net have provided further evidence in that 51Cr re-
lease studies, antibody-dependent CdC, as a sen-
sitive indicator of cellular and humoral immunity
of the recipient against the donor, correlated with
graft rejection (32; Jeannet, personal communica-
tion). It is not known for which non-HLA System
incompatibility was detected. Several other Sys-
tems in animals have been shown to be of possible
relevance for bone marrow transplantation: the Hh
and Mli Systems in the mouse and the colonic se-
cretion System W/Z in the dog (7,12,34). Whether
analogous Systems exist in man has not been de-
termined. In this context, it is of significance that,
for the detection of all these determinants, tech-
niques other than the CdC technique are necessary.
Furthermore, the target cells in these techniques
will also be different from the mononuclear cell sus-
pension routinely used in the CdC technique. The
European Bone Marrow Transplant Cooperative
Group plans to make the technical facilities nec-
essary to carry out these tests available to its mem-
bers.
CAN HLA-IDENTICAL, UNRELATED
DONORS BE USED IN BONE
MARROW TRANSPLANTATION?
The question can be answered, in all probability,
in the affirmative. But only a few of these trans-
plants have been attempted. With the possible ex-
ception of one case, none was successful (10). But
ericouragement is given by a small number of mixed
leukocyte culture (MLC) negative haplo-identical
transplants (parent-child, siblings) from non-inbred
families, several of which have been reported to be
successful (6). It must be assumed that if it is pos-
sible to match successfully for one "unrelated"
haplotype, it should also be possible to match for
two. The lesson here is that if no HLA-identical
sibling is available, one should not despair but look
for other MLC-negative family members. An added
advantage is that parents have a good chance of
being identical for non-HLA loci.
The question then can be asked whether one
should match for the SD or HLA-A, -B, and -C
antigens or the MLC-stimulating determinants or
both. In man, sufficient data are of course not avail-
able. Furthermore, no data are available for outbred
mice and only limited data for the dog (27,31). Most
critical would be studies in monkeys, which will
probably soon be forthcoming.
Because bone marrow transplant data in exper-
imental animals are lacking, it seems reasonable to
ask whether other transplants in man may indicate
what to expect. Table 20-4 summarizes experimen-
tal skin transplants in man, and these are a much
more severe test of compatibility than are bone
marrow transplants. It is clear that a negative MLC
is a more effective way to improve skin graft sur-
vival than SD matching, but the combination of the
two is still better. The 17-day mean graft survival
that can be obtained in this manner is not much
shorter than that obtained in HLA-identical siblings
in our laboratory (19 days). Similar data are avail-
TABLE 20-4 Skin Graft Survival and Matching for HLA
HLA-A and
HLA-B
Nonidentical
Identical
Nonidentical
Identical
MLC
+
+
-
-
MEAN SURVIVAL
Time ± S Ε
(days)
10.0 ± 1.08
11.8 ± 0.59
14.4 ± 2.07
17.3 ± 2.5
NUMBER
13
20
5
4
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TABLE 20-5 The Recognition of HLA D Determmants by Β Cell Serology
HLAD ΑΝΤΙ Β CELL SERUM
HLA D ΑΝΤΙ Β CELL
SERUM
+ - + -
+ + - ~
GENE FREQUENCIES
DEFINED BY
HTC Anti Β cell sera
DW1
DW2
DW3
DW4 (+ 7)
DW5
DW6 (+ 2)
LD 107
LD 108
He
Du
CB
RD
Moa
WH
Smith (Bodmer)
Pichon (Dausset)
Po
Si
TL (Thorsby)
11
Β
9
27
16
20
8
14
15
0
0
0
0
0
2
10
5
4
1
0
4
0
1
4
0
4
1
2
8
0
7
19
21
47
44
34
39
30
45
35
45
26
0 0889
0 1287
0 1462
0 0669
0 0412
0 0458
0 0672
0 1039
0 1339
0 1229
0 2033
0 1229
0 0906
0 1229
0 1451
0 0594
0 6888 1 0010
TZ υ , Α ΙΛ h„ ΗΤΓ anrt PI Τ and was then studied by sera recogmzing
The panel was first typed for HLA D by HTC and PL1 ana was
determmants The fit of the Β cell typmg w,th PLT « ^ c t e d H T C ty^ng s rem rtfaMy«
 H T C
nants 1t is clear that the sum of the gene frequencies of the H L A ^ C ^ » » ™h n a m e s o f t £ e inVestigators
much smaller than .f the HLA D determmants had been ^ ^ J ^ w r o t o g ^ I £ η ^ ^
who made these sera available are given in parentheses The rematnder ot tne sera we
able for kidney grafts (5) The question is, How
does one obtain unrelated donors who are identical
for the HLA-A, -B, and -C antigens and MLC neg-
ative with the recipient Large numbers of donors
have been HLA typed, with the intention of using
them for platelet and granulocyte support therapy,
and some of these donors are wilhng to donate bone
marrow In Europe alone, the files already exceed
50,000 HLA-typed donors Thus, lt would be pos-
sible to select, in many instances, for a given pa-
tient a donor who is at least HLA-A and -B
matched Those donors who are MLC negative
with the recipient could be further selected by di-
rect MLC testing This is, however, a labonous
procedure and when the patient has only a few lym-
phocytes, lt will be difficult lf not lmpossible to
reahze
Recently, lt has become possible to type for the
alleles of the strong MLC-stimulating HLA-D locus
usmg serological techniques (22) (Table 20 5)
There are only eight alleles for HLA D (30) lt is
quite possible that some of the HLA-D specificities
will be split in two ormore determmants, as was
the case for the HLA-A and Β locus antigens
Nevertheless, as Table 20 6 shows, matching for
even this small number of alleles increases MLC
negativity from piactically 0 percent in the HLA-D
different combmations through 25 percent in the
SD nonidentical, HLA-D-identical combination, to
nearly 80 percent in the SD- and HLA-D-idenücal
combmations These data confirm and extend ear-
lier observations and prove that MLC reactivity is
governed not only by loci in the HLA-D region, but
also by loci near HLA-A and/or -B These findmgs
have furthermore a number of theoretical and prac
TABLE 20-6 Matching for HLA Α Β and D
Outcome of the MLC Test
Α and
ψ
\
HLA
-B -D
{
MLC
< 2
1
0
15
10
STIMULAT
INDEX
2-8
65
11
26
2
tical implications From the practical point ο
the findings are clear cut Identity at HLA
and -D implies a 80 percent chance of a η
MLC The loci responsible for the remair
percent could be outside HLA and should b
tified From the theoretical point of view
findings are less simple The one MLC η
HLA-A, -B, and -D disparate combination
conflicts with most accepted theones on MI
ing Short of a technical error, which is ui
lt can only be explamed by non-reactive clo
was first descnbed by Svejgaard's group 0
dividuals who are mismatched for HLA
HLA-B, but matched for HLA-D, producc
mficant Stimulation presumably because of
ences for loci identical with or near to HLA
or Β
lt is clear that, until now, our view on the
anism of strong MLC Stimulation has been s
tic lt is even possible that an equivalent of
2 I-J locus coding for determmants on supi
cells exists in man and that dispanty for
locus can suppress MLC activation (28) 1
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Lourse, too early to know whether these findings
can be used in the selection of unrelated donors for
bone marrow transplantation, but lt IS equally clear
that we ought to find out For the time being, our
attitude should be one of extreme caution If at all
possible, we should wait until data from Rhesus
monkeys are available Until that time, only SD-
ldentical, MLC-negative donors should be used and
the CML test should also be negative
THE INFLUENCE OF SENSITIZATION
ON THE EFFECTIVENESS OF
IMMUNOSUPPRESSION
Gluckman et al have shown that the responsive-
ness of the patient, ι e , his or her capacity to form
immunity against major histocompatibility complex
(MHC) determinants and other antigens, and the
effect immunosuppression has on this immunity,
correlates with bone marrow graft prognosis and
especially rejection (13) The immunological capac-
ity of both patient and donor are thus variables to
j
 reckon with, and the question whether we can ιη-
fluence lt by other means than chemotherapy alone
is thus a relevant one Although we know that anti-
HLA-A, and -B antibodies in the recipient will de-
- stroy most kidney grafts from incompatible donors,
lt is equally certain that kidney grafts in recipients
who had received no blood transfusions before
transplantation have a graft prognosis that is ex-
tremely poor less than 20 to 30 percent of the grafts
function at 1 year in the non-transfused group, ver-
sus 70 percent in the transfused group (17,20) Bai-
ner and his colleagues have confirmed these find-
mgs in a randomized prospective study in Rhesus
> monkeys (9) The unexpected observation was that
e whereas immunosuppression alone (Standard doses
0 of Imuran and prednisone) after transplantation had
ι no effect on graft survival, the combination of lm-
e munosuppression after transplantation with blood
e transfusions before transplantation had a very sig-
d mficant effect (Figure 20-1)
t The mechamsm for this very effective graft pro-
, longation is completely unclear (competition,
s suppression cell induction, enhancing antibodies7)
ι But even if the mechamsm is unknown, lt might
d still be of interest to test whether it could be used
r
- to suppress the GvH reactivity of the donoi, es-
pecially against non-HLA determinants It might be
1/ a relaüvely small pnce for the donor to pay if this
could prevent GvHD in the reupient
SUMMARY
ι With the help of the lmmunofluorescence test,
Λ pldtelet antibodies can be detected and compatible
»f platelets selected Such platelets, if HLA compat-
A
MST
MST
0 7 14 21 28 35 42 49 56 63 70 100
MST
Survival time (days)
FIGURE 20-1 The influence of blood transfusion on
kidney allograft survival in unrelated Rhesus monkeys
(A) Non transfused/no immunosuppression mean sur
vival time (MST) 11 4 days (B) non transfused/immu
nosuppression MST 110 days transfused/immuno
suppression MST 48 8 days Repnnted with permission
of Lancet (see reference 9)
lble, have a nearly 100 percent survival rate, even
in hypenmmunized patients The use of lympho-
cyte-free platelets for transfusion, which can be
easily obtained by three-step differential centnfu-
gation, prevents lmmunization in over 70 percent
of the recipients
The cell mediated lympholysis (CML) test and
a complement-dependent cytotoxicity (CdC) test
can be used to detect HLA-restncted, anti-H-Y im-
munity in some lmmunized women This might ex-
plain, in part, the poorer prognosis of the sex-mis-
matched bone marrow giafts
In the future, if HLA-identical sibhngs of pa-
tients are not available or suitable for bone marrow
transplantation, unrelated HLA-identical donors
might take their place Chnical ddta obtained with
other organ transplants indicate that prognosis
when the donor is unrelated might be comparable
or better than that of HLA-identical sibhng donors
Thus, HLA-D-identical donors can be found rela-
tively easily because it is now possible to type for
HLA-D serologically The HLA-A, -B, and -D-
ldentical, donor-recipient pairs are in mixed leu-
kocyte culture (MLC) negative about 80 percent of
the cases
If blood transfusions are combined with chemo-
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therapy (Imuran and prednisone), very effective
"immunosuppression" can be obtained in kidney
transplantation It would be of interest to test
whether such a procedure could be used to increase
the number of successful bone marrow transplants
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